Depending who you ask, AI-powered coding is either giving software developers an unprecedented productivity boost or churning ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P Morgan Healthcare Conference. But some ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a ...

Despite a year of trade tensions, national security strictures and stark warnings about the U.S.’ waning biotech innovation edge, the fact remains that China is and will likely continue to be a ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

The real estate investment trust sold off hundreds of millions of dollars worth of medical buildings to fund its latest ...